ViiV Healthcare announces reimbursement for Apretude for HIV-1 pre-exposure prophylaxis under the Non-Insured Health Benefits (NIHB) Program

25 March 2025 - ViiV Healthcare is pleased to announce that Apretude (cabotegravir tablets and extended release injectable suspension) is ...

Read more →

Government of Canada signs bilateral agreement with Quebec for Drugs for Rare Diseases

21 March 2025 - In Canada, one in 12 people live with a rare disease, and for most people affected, the ...

Read more →

Canada’s Drug Agency publishes new guidance for rare disease registries in Canada

28 February 2025 - On Rare Disease Day — a global event dedicated to raising awareness for the millions of ...

Read more →

Bimzelx (bimekizumab) negotiations with pCPA concluded successfully following positive CDA and INESSS recommendations for adults with active psoriatic arthritis and adults with active ankylosing spondylitis

28 February 2025 - Positive CDA and INESSS reimbursement recommendations are an important step towards public access to Bimzelx, the first ...

Read more →

Government of Canada signs Pharmacare agreement with Manitoba to improve affordable access to medications

27 February 2025 - Additional agreement will improve access and affordability of drugs for rare diseases. ...

Read more →

ViiV Healthcare and the pan-Canadian Pharmaceutical Alliance successfully finalise negotiations for Apretude for HIV-1 pre-exposure prophylaxis

13 February 2025 - ViiV Healthcare is pleased to announce it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance ...

Read more →

Drugs for rare diseases – Ontario agreement

24 January 2025 - Today, the Governments of Canada and the province of Ontario signed the National Strategy for Drugs ...

Read more →

International collaboration provides new guidance on the use of surrogate endpoints in cost effectiveness analysis

9 January 2025 - Recommendations will help organisations that appraise new drugs establish whether their use will result in longer-term ...

Read more →

Alnylam Canada signs letter of intent from pan-Canadian Pharmaceutical Alliance for the public reimbursement of Amvuttra for the treatment of hereditary transthyretin-mediated amyloidosis in adults

18 October 2024 - One step closer to achieving public reimbursement of Amvuttra for hereditary transthyretin-mediated amyloidosis. patients in Canada ...

Read more →

Government of Canada signs bilateral agreement with Alberta to improve access to drugs for rare diseases

5 December 2024 - Today, the Honourable Mark Holland, Canada's Minister of Health, and the Honourable Adriana LaGrange, Alberta's Minister ...

Read more →

Canada’s Drug Agency launches consultation on methods guide

28 November 2024 - Canada’s Drug Agency is launching a consultation on its first ever methods guide.  ...

Read more →

Lilly Canada remains steadfast in commitment to access options for patients amidst controversial CDA-AMC recommendation for Ebglyss (lebrikizumab)

19 November 2024 - Eli Lilly Canada is disappointed and strongly disagrees with Canada's Drug Agency (CDA-AMC)'s Final Recommendation for Ebglyss ...

Read more →

Canada's Drug Agency recommends Winrevair (sotatercept) for reimbursement

8 November 2024 - Merck announced that Canada's Drug Agency has recommended Winrevair (sotatercept) for reimbursement in combination with standard ...

Read more →

NS parents dismayed by lack of access to new RSV vaccines for infants

3 November 2024 - Officials say there is no universally available, publicly funded RSV vaccine program for newborns in Nova Scotia. ...

Read more →

Differences in drug shortages in the US and Canada

31 October 2024 - In this cross-sectional study, there were 104 reports of drug-related supply chain issues that occurred from 2017 ...

Read more →